share_log

Cantor Fitzgerald Maintains Overweight on Marinus Pharma, Lowers Price Target to $4

Benzinga ·  Oct 26 00:16  · Ratings

Cantor Fitzgerald analyst Charles Duncan maintains Marinus Pharma (NASDAQ:MRNS) with a Overweight and lowers the price target from $13 to $4.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment